Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations-Reference-Cited by-同舟云学术

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations

Published:2017-01 Issue:1 Volume:28 Page:136-141
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Iwama E.,Sakai K.,Azuma K.,Harada T.,Harada D.,Nosaki K.,Hotta K.,Ohyanagi F.,Kurata T.,Fukuhara T.,Akamatsu H.,Goto K.,Shimose T.,Kishimoto J.,Nakanishi Y.,Nishio K.,Okamoto I.

Funder

Boehringer-Ingelheim

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/1/136/10296976/mdw531.pdf

Reference16 articles.

1. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

2. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials;Yang;Lancet Oncol,2015

3. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations;Sequist;J Clin Oncol,2013